The RWE Data Moat Is About to Change

Posted on: October 07^th 2026

Why the next generation of RWE platforms may be defined not by how much data they own, but by how much of that data they can turn into intelligence

Real-world evidence companies have spent years building something exceptionally difficult to replicate: large, proprietary collections of healthcare data.

Claims. EHRs. Pharmacy data. Physician notes. Clinical evidence. Trial protocols. Payer information. Literature.

Healthcare analytics and real-world data (RWD) providers sit on data assets with enormous potential. Yet having the data is not the same as being able to reason across it.

The most valuable questions in real-world intelligence rarely live neatly inside a single table or document.

• Why did a patient switch therapies?
• What happened before and after the switch?
• Which clinical factors influenced the trajectory?
• How did that pattern differ across populations?
• Which patients in a real-world dataset most closely resemble a clinical trial population?
• What combination of treatment history, comorbidities and outcomes explains an observed signal?

These are not simply search questions. They are questions about relationships, chronology, context and evidence.

And that creates an interesting strategic possibility for RWE companies:

The next data moat may not come from acquiring more data. It may come from making more of the data you already own computable.

At Straive, we believe this is where the next generation of AI-enabled healthcare data platforms can begin to differentiate, not by adding another conversational interface to existing data, but by changing how proprietary data is structured, connected and interrogated.

1. Your data moat is probably bigger than the data you can currently query

For years, the industry has become exceptionally good at making structured healthcare data usable.

Claims data can tell us what was coded.

• Pharmacy data can tell us what was dispensed.
• Structured EHR data can tell us what was recorded.
• But some of the most important context sits elsewhere.
• A physician note may explain why a treatment changed.
• A pathology report may provide nuance that a structured field cannot capture.
• A clinical protocol may reveal relationships between eligibility criteria that are difficult to represent in a conventional query.

The opportunity is therefore not simply to extract more information. It is to connect the existing information.

This is one of the areas where Straive sees a meaningful role for AI-enabled semantic data engineering: using LLMs to extract entities, relationships and context from unstructured healthcare content, then normalize that information into a representation that can participate in downstream analytical workflows.

The source architecture describes this as an LLM-driven extraction pipeline that feeds a lightweight, queryable graph, rather than leaving valuable unstructured content as a passive repository.

The implication for RWE platforms is significant.

Your competitive advantage may increasingly depend not just on the breadth of your data, but on how much of that breadth can be activated in a product or analytical workflow.

2. You don’t need to build another giant ontology

This is where the traditional knowledge-graph playbook runs into a very modern problem.

Historically, building a useful knowledge graph often meant creating extensive ontologies, defining relationships upfront and relying heavily on subject-matter experts to curate and maintain the structure.

• That can produce powerful systems.
• It can also take a long time to become useful.

The alternative that emerged with GenAI was almost the opposite: forget the structure, put the documents into a vector database, retrieve the most relevant passages and let the model generate the answer.

• That solves some problems.
• It does not solve all of them.

For complex healthcare intelligence, abandoning semantic structure entirely can create another problem: fragmented entities, ambiguous relationships and difficulty tracing how an answer was derived. The source characterizes this as the risk of a “knowledge hairball” when ontologies disappear altogether.

The more pragmatic opportunity is what we call a Just-in-Time Ontology.

Instead of designing a universal ontology before the first use case, define the minimum semantic structure required for the question you are trying to answer.

• Extract it.
• Normalize it.
• Build the relevant relationships.
• Then expand the model as new questions require it.

In this model, LLMs become the extraction engine rather than the final source of truth. Human experts become strategic editors who resolve important edge cases rather than manually curating every record.

That changes the economics of semantic data work.

The question is no longer:

“Can we afford to build a knowledge graph?”

It becomes:

“Where would a small, purpose-built semantic layer create enough value to justify building it?”

That is a much more useful question for an RWE product leader.

3. Retrieval is not the same as reasoning

This is perhaps the most important distinction in the current AI conversation.

Standard retrieval-augmented generation is very good at helping a model find relevant information.

But consider a question like:

What happened to patients after switching from therapy A to therapy B, and how did that trajectory differ by comorbidity and prior treatment history?

Answering that reliably may require connecting multiple records across time, reconciling structured and unstructured evidence, and traversing relationships between patients, diagnoses, treatments and outcomes.

The answer does not necessarily exist in one document.

It emerges from connections across documents and events.

This is where a hybrid GraphRAG architecture becomes interesting.

A simplified pattern looks like this:

Claims + EHR + clinical notes + trial protocols + literature

→ LLM-driven extraction

→ Just-in-Time Ontology

→ Longitudinal Patient & Evidence Graph

→ Specialized analytical agents

→ Evidence-backed answer

The architecture described in the source combines multimodal document indexing with a longitudinal evidence graph, then adds specialized agents for RWE/epidemiology, clinical trials, and HEOR/market access.

The distinction matters because the value proposition for an RWE platform is not merely:

“Ask questions of your data.”

It is:

“Investigate relationships across your data.”

That is a much richer product proposition.

4. The real differentiator will be evidence fidelity

For many enterprise AI applications, a plausible answer may be enough to move a workflow forward.

For RWE companies, the standard is different.

These organizations are ultimately providing evidence and intelligence to customers who may challenge the basis for a finding.

That means a useful AI answer needs more than fluency.

• It needs context.
• It needs provenance.
• It needs the ability to distinguish between different kinds of evidence.

And, in higher-risk situations, it needs a mechanism for human review.

A governed architecture can therefore incorporate source hierarchies, contradiction detection, confidence or risk scoring, and human-in-the-loop review.

For example, the source proposes a reasoning and evaluation layer capable of identifying contradictions between structured and unstructured evidence, while a governance layer establishes business rules and source priorities.

This creates an important shift in thinking:

For RWE platforms, governance is not only a control mechanism. It can become part of the product experience.

Imagine an analyst asking an AI system a question and receiving not just an answer, but the evidence chain behind it:

• What records contributed?
• Which relationships were used?
• Where did sources disagree?
• What assumptions were applied?
• What requires expert review?

That is much closer to an investigation environment than a chatbot.

5. The biggest opportunity may be new products—not better versions of old ones

This may ultimately be the most important strategic implication.

Most RWE platforms have traditionally organized value around some combination of:

Data → analytics → dashboard → consulting or report

GenAI introduces the possibility of a different interaction model:

Proprietary data → investigation layer → natural-language question → evidence-backed intelligence

That could change not just how customers consume an existing product, but what the product itself is.

The source describes one such direction as an “Investigation Workbench”: a natural-language interface through which clients can dynamically interrogate patient journeys and other proprietary data assets.

This opens several possibilities.

• A data platform could make previously difficult unstructured assets more useful.
• A consulting organization could reduce the latency involved in answering custom analytical questions.
• A technology platform could create new premium capabilities around proprietary data.

And a commercial organization could differentiate its offering in a market where simply saying “we have GenAI” is no longer enough.

In other words:

The opportunity is not merely to use AI to speed up the existing RWE product. It is to use AI to redefine what the RWE product can be.

So where should RWE companies start?

The answer is probably not with a massive enterprise-wide knowledge graph program.

Nor is it with “put all our documents into a vector database.”

A more practical starting point is one high-value question.

Choose a workflow where:

• Important information is split across structured and unstructured sources;

• Relationships across time or entities matter;

• Current approaches require significant analyst effort;

• Provenance and evidence quality matter, and

• The result could eventually become part of a differentiated product or service.

From there, build the smallest useful semantic layer.

• Use LLMs to accelerate extraction.
• Create the relevant evidence graph.
• Introduce a focused analytical agent.

Then measure what changed: time-to-insight, analyst effort, evidence traceability, quality of results, and potential product value.

That approach also allows organizations to test the architecture without committing prematurely to an enterprise-wide semantic transformation.

The next RWE advantage may be hidden in plain sight

The RWE industry has already invested heavily in acquiring, curating, and organizing healthcare data.

The next competitive question may be simpler:

How much of that data can you actually reason over?

Companies that answer that question well could unlock more value from their existing assets, particularly the unstructured and longitudinal evidence that remains difficult to interrogate using traditional data architectures.

At Straive, our view is that this requires a pragmatic combination of LLM-driven extraction, lightweight semantic structures, graph-based context, specialized agents, and governed reasoning rather than a choice between “old-school knowledge graphs” and “pure GenAI.”

The strategic opportunity is not to replace the data platform.

It is to make the data platform more intelligent, more investigable, and more commercially valuable.

And that may be where the next RWE data moat begins.